Guidance for the 2026/27 financial year

ChemoMetec guided FY2026/27 revenue to DKK 545-575 million, implying growth of approximately 7%-13% from FY2025/26 revenue of DKK 511.1 million. EBITDA is expected at DKK 300-315 million versus DKK 281.3 million, representing roughly 7%-12% growth and indicating continued high profitability. The outlook is a constructive company-specific catalyst for the cell-analysis instrument provider.

Analysis

The key investment question is not the modest top-line acceleration but whether ChemoMetec can sustain an EBITDA margin above 54% while expanding its installed base. At this margin level, incremental consumables and service revenue should convert disproportionately into free cash flow; however, the narrow guidance range suggests management has relatively high visibility and leaves limited room for a major near-term estimate beat absent stronger order intake or a favorable mix shift toward higher-throughput biopharma applications.

CHEMM's strategic upside is tied to cell-therapy and biologics manufacturing capacity additions, where validated cell-counting workflows create switching costs and recurring consumables pull-through. The second-order beneficiary is not a broad life-science-tools basket: larger workflow vendors such as Danaher (DHR), Sartorius (SRT3) and Agilent (A) have adjacent exposure, but CHEMM can take share where customers prioritize instrument simplicity and lower total workflow cost. Conversely, a prolonged biotech funding recovery could favor diversified peers more immediately because their consumables portfolios are broader.

Over the next 1-3 months, the stock's reaction will depend on whether the annual report substantiates organic volume growth rather than price/mix or currency effects, and whether management quantifies order-book and consumables trends. Over 6-18 months, the primary risk is that pharmaceutical customers defer capacity projects, producing weak instrument placements that only become visible later through slower recurring-revenue growth. The thesis is falsified by quarterly revenue tracking below the low end of the implied run-rate, EBITDA margin falling below roughly 53%, or a material reduction in biopharma customer capex expectations.

Consensus may overemphasize the headline earnings growth and underappreciate valuation risk: companies with CHEMM's margin profile can de-rate sharply if growth settles into mid-single digits, even with intact profitability. The constructive contrarian case is that margin durability is evidence of a defensible niche rather than underinvestment; confirmation requires recurring revenue growing faster than instrument sales and no increase in sales-and-marketing intensity.

Key Decisions for Investors

• Maintain a watchlist/accumulate-on-confirmation stance in CHEMM rather than chase the initial guidance reaction. Initiate only if the annual-report disclosures show recurring consumables/service growth at or above total revenue growth and the shares do not re-rate materially beyond the growth implied by the 2026/27 midpoint; target a 6-12 month holding period.
• For an existing CHEMM long, retain exposure through the next quarterly update but size for execution risk. Add only on evidence that revenue is tracking above the DKK 560 million midpoint run-rate while EBITDA margin remains at least 54%; reduce if management attributes growth primarily to nonrecurring instrument deliveries or FX.
• Use DHR or SRT3 as a relative-value hedge against a broad life-sciences recovery trade: long CHEMM / short a small basket of DHR and SRT3 is appropriate only if CHEMM demonstrates superior organic consumables growth. The pair is invalidated if large-cap peers show accelerating bioprocess orders while CHEMM's placement activity stalls.
• Set an alert for biopharma manufacturing-capex indicators and CHEMM order-intake commentary over the next two reporting periods. A weakening of either before revenue misses emerge would be an early signal to exit, as instrument-order softness typically precedes recurring-consumable deceleration by several quarters.